A Trial of the Efficacy, Safety and Impact on Drug Resistance of Four Drug Regimens for Seasonal Intermittent Preventive Treatment for Malaria in Senegalese Children
2008

Efficacy of Four Drug Regimens for Preventing Malaria in Senegalese Children

Sample size: 2020 publication 10 minutes Evidence: high

Author Information

Author(s): Sokhna Cheikh, Cissé Badara, Bâ El Hadj, Milligan Paul, Hallett Rachel, Sutherland Colin, Gaye Oumar, Boulanger Denis, Simondon Kirsten, Simondon François, Targett Geoffrey, Lines Jo, Greenwood Brian, Trape Jean-François

Primary Institution: Institut de Recherche pour le Développement, Dakar, Senegal

Hypothesis

Is the SP+3AQ regimen more effective than other regimens in preventing malaria in children?

Conclusion

Monthly treatment with SP+3AQ is highly effective for seasonal malaria prevention and minimizes drug resistance.

Supporting Evidence

  • The SP+3AQ group had the lowest incidence of malaria at 4.9%.
  • The study included 2020 children who were treated and followed up.
  • The SP+3AQ regimen was twice as effective as the previously used SP+1AS regimen.

Takeaway

This study tested different medicines to see which one works best to stop kids from getting malaria, and found that one combination worked really well.

Methodology

An open-label trial comparing four treatment regimens in 2020 children aged 6–59 months.

Potential Biases

Potential bias due to non-random allocation and lack of blinding.

Limitations

The trial was not blinded, which may have influenced reporting of adverse events.

Participant Demographics

Children aged 6–59 months, with a mean age of 32 months, 49% male.

Statistical Information

P-Value

0.006

Confidence Interval

95% CI 0.30–0.81

Statistical Significance

p=0.006

Digital Object Identifier (DOI)

10.1371/journal.pone.0001471

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication